Management of acute and chronic gouty arthritis: Present state-of-the-art

Drugs

Volumn 64, Issue 21, 2004, Pages 2399-2416

  Schlesinger, Naomi ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ALLOPURINOL; BENZBROMARONE; COLCHICINE; CORTICOTROPIN; FEBUXOSTAT; FENOFIBRATE; INDOMETACIN; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OXIPURINOL; PREDNISOLONE; PREDNISONE; PROBENECID; SULFINPYRAZONE; TRIAMCINOLONE; TUBULIN; UNCLASSIFIED DRUG; URATE OXIDASE; URIC ACID; URICOSURIC AGENT; URICOZYME; XANTHINE OXIDASE INHIBITOR;

ALCOHOL CONSUMPTION; ARTHRALGIA; BACKACHE; BONE MARROW SUPPRESSION; CHEMOPROPHYLAXIS; CHRONIC ARTHRITIS; CLINICAL FEATURE; CLINICAL TRIAL; CRYOTHERAPY; DIARRHEA; DIET RESTRICTION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; EOSINOPHILIA; FEVER; GASTROINTESTINAL SYMPTOM; GOUT; GRANULOCYTOPENIA; HEADACHE; HEPATITIS; HUMAN; INCIDENCE; KIDNEY FAILURE; LIVER TOXICITY; PAIN; PATHOPHYSIOLOGY; PREVALENCE; RASH; REVIEW; SEIZURE; SHOCK; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOPHLEBITIS; TOXIC EPIDERMAL NECROLYSIS; VOMITING; WEIGHT REDUCTION;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, GOUTY; CHRONIC DISEASE; CLINICAL TRIALS; COLCHICINE; FEMALE; GOUT SUPPRESSANTS; HUMANS; INCIDENCE; MALE; PREVALENCE; URICOSURIC AGENTS;

EID: 8344222080     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464210-00003     Document Type: Review

References (107)

1. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med 1987; 82: 421-6
2. Yu TF, Gutman AB. Uric acid nephrolithiasis in gout: predisposing factors. Ann Intern Med 1967; 67: 1133-48
3. Wortmann RL. Effective management of gout: an analogy. Am J Med 1998 Dec; 105: 513-4
4. Grahame R, Scott JT. Clinical survey of 354 patients with gout. Ann Rheum Dis 1970; 29: 461-8
5. Weede RP. Poison in the pot: the legacy of lead. Carbondale (IL): Southern Illinois University Press, 1984: 83
6. Comrie JD, editor. Selected works of Thomas Syndenham MD with a short biography and explanatory notes. London: Bale J, Sons and Danielson, 1922
7. Bacethge BA, Work J, Landreneau MD, et al. Tophaceous gout in patients with renal transplantation treated with cyclosporine A. J Rheumatol 1993; 20: 718-200
8. Wernick R, Winkler C, Campbell S. Tophi as the initial manifestation of gout: report of six cases and review of the literature. Arch Intern Med 1992; 152: 873-6
9. Roubenoff R, Klag MJ, Mead LA, et al. Incidence and risk factors for gout in white men. JAMA 1991; 266: 3004-7
10. Lawrence RC, Hochberg MC, Kelsey JL, et al. Estimates of the prevalence of selected arthritis and Musculoskeletal disease in the United States. J Rheumatol 1989; 16: 427-41
11. Mikkelson WH, Dodge HJ, Valkenberg H. The distribution of plasma uric acid values in a population unselected as to gout and hyperuricemia. Am J Med 1965; 39: 242-51
12. O'Sullivan JB. Gout in a New England town: a prevalence study in Sudbury Massachusetts. Ann Rheum Dis 1972; 31: 166-9
13. Perkins P, Jones AC. Gout. Ann Rheum Dis 1999; 58: 611-61
14. Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol 2000; 11: 974-9
15. Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey, 1996. Series 10. No. 200 [online]. Available from URL: http://www.cdc.gov/nchs/data/series/sr_10/10_200_1.pdf [Accessed 2003 Jan 5]
16. Klemp P, Shelley A, Stansfield SA, et al. Gout is on the increase in New Zealand. Ann Rheum Dis 1997; 56: 22-6
17. Healy LA, Skeith MD, Decker JL, et al. Hyperuricemia in Filipinos: interaction of heredity and environment. Am J Hum Genet 1967; 19: 81-5
18. Schlesinger N, Baker DG, Beutler AM, et al. Acute gouty arthritis is seasonal. J Rheumatol 1998; 25: 342-4
19. Boss GR, Seegmiller JE. Hyperuricemia and gout: classification, complications and management. N Engl J Med 1979 Jun 28; 300 (26): 1459-68
20. Hall AP, Berry PE, Dawber TR, et al. Epidemiology of gout and hyperuricemia: a long-term population study. Am J Med 1967; 42: 27-37
21. Perez-Ruiz F, Calabozo M, Erauskin GG, et al. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum 2002; 47 (6): 610-3
22. McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med 1961; 54: 452-60
23. Lally EV, Zimmerman B, Ho G, et al. Urate mediated inflammation in nodal arthritis: clinical and roentgenographic correlations. Arthritis Rheum 1989; 32: 86-90
24. Reginato AJ, Schumacher Jr HR. Crystal associated arthropathies. Clin Geriatr Med 1988; 4: 295-322
25. Weinberger A, Schumacher HR, Agudelo CA. Urate crystals in asymptomatic metatarsophalangeal joints. Ann Intern Med 1979; 92: 56-7
26. Bomalaskj JS, Lluberas G, Schumacher Jr HR. Monosodium urate crystals in the knee joints of patients with asymptomatic nontophaceous gout. Arthritis Rheum 1986; 29: 1480-4
27. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895-900
28. Schlesinger N, Baker DG, Schumacher Jr HR. Gout: how well have diagnostic tests and therapies been evaluated? Curr Opin Orthop 2000; 11: 71-6
29. Schlesinger N, Baker DG, Schumacher Jr HR. Gout: can management be improved? Curr Opin Rheumatol 2001; 13 (3): 240-4
30. Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kimmen. J Rheumatol 2000; 27: 1045-50
31. Lin KC, Lin HY, Chou P. The interaction between SUA level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 2000; 27: 1501-5
32. Nicholas A, Scott JT. Effect of weight loss on plasma and urinary levels of uric acid. Lancet 1972; II: 1223-4
33. Fam AG. Gout, diet, and the insulin resistance syndrome. J Rheumatol 2002; 29: 1350-5
34. Dessein PH, Shipton AE, Stanwix AE, et al. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 2000; 59: 539-43
35. Sharpe CR. A case controlled, study of alcohol consumption and drinking behaviour in patients with acute gout. CMAJ 1984; 131: 563-7
36. Agudelo CA, Schumacher Jr HR, Phelps P. Effect of exercise on urate crystal-induced inflammation in canine joints. Arthritis Rheum 1972; 15: 609-16
37. Schumacher Jr HR. Crystal induced arthritis: an overview. Am J Med 1996; 100 Suppl. 2A: 46-52
38. Schlesinger N, Baker DG, Beutler AM, et al. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 2002; 29: 331-4
39. Dorwart BB, Hansell JR, Schumacher Jr HR. Effects of cold and heat on urate-induced synovitis in dog. Arthritis Rheum 1974; 17: 563-71
40. Pittman JR, Bross MH. Prognosis and management of gout. Am Fam Physician 1999; 59: 1799-806
41. Carew M, Roberts K. Care of the patient with gout. Geriatr Nurs 2000; 20: 156-7
42. Porter R, Rousseau GS, editors. Gout: the patrician malady. New Haven (CT): Yale University Press, 1998
43. Singer C. A history of scientific ideas. New York: Barnes and Noble Books, 1996
44. Peletier PS, Caventon J. [Title unknown]. Ann Chim Phys 1820; 14: 69
45. Corrodi H, Hardegger E. Die Konfiguration des Colchicins und verwandter Verbindungen. Helv Chem Acta 1955; 38: 2030-3
46. Katzung BG, editor. Basic and clinical pharmacology. 6th ed. Norwalk (CT): Appleton and Lange, 1995: 536-59
47. Levy M, Spino M, Read SE. Colchicine: a state-of-the-art review. Pharmacotherapy 1991; 11: 196-211
48. Ahern MJ, Reid C, Gordon TP. Does colchicine work? Results of the first controlled study in gout. Aust N Z J Med 1987; 17: 301-4
49. Paulus HE, Schlosstein LH, Godfrey RC, et al. Prophylactic colchicine therapy in intercritical gout. Arthritis Rheum 1974; 17: 609-14
50. British National Formulary 48. London: British Medical Association, Royal Pharmaceutical Society of Great Britain, 2004 [online]. Available from URL: http://www.bnf.org/bnf/bnf/48/openat/5311.htm?q=%22colchicine%22 [Accessed 2004 Sep 27]
51. Morris I, Varughese G, Mattingly P. Colchicine in acute gout. BMJ 2003; 327: 1275-6
52. Wallace SL, Singer JZ. Review; systemic toxicity associated with the intravenous administration of colchicine: guidelines for use. J Rheumatol 1988; 15: 495-9
53. Guazzo E. Use of intravenous colchicine for podagra [letter]. Am Fam Physician 1999; 60: 2504-5
54. Stephan WH. Use of intravenous colchicine in patients with acute gout [letter]. Am Fam Physician 2000; 61: 2343-4
55. Evans IT, Wheeler MT, Small RE, et al. A comprehensive investigation of inpatient colchicine use shows more education is needed. J Rheumatol 1996; 23: 143-8
56. Allison MC, Howatson AG, Torrance CJ, et al. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med 1992; 327: 749-54
57. Sandler DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991; 115: 165-72
58. Kelly W, Wortmann RL. Crystal-associated synovitis: gout and hyperuricemia. In: Kelly W, editor. Textbook of rheumatology. 4th ed. Philadelphia (PA): Saunders, 1993: 1340-51
59. Smyth CJ, Percy JS. Comparison of indomethacin and phenylbutazone in acute gout. Ann Rheum Dis 1973; 32 (4): 351-3
60. Ruosti A, Vainio U. Treatment of acute gouty arthritis with proquazone and indomethacin: a comparative double-blind trial. Scand J Rheumatol Suppl 1978; 21: 15-7
61. Altman RD, Honig S, Levin JM, et al. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J Rheumatol 1988; 15: 1422-6
62. Weiner GI, White SR, Weitzner RI, et al. Double blind study of phenoprofen versus phenylbutazone in acute gouty arthritis. Arthritis Rheum 1979; 22: 425-6
63. Shrestha M, Morgan DL, Moreden JM, et al. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med 1995; 26: 682-6
64. Maccagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac (Lodine) compared with naproxen in patients with acute gout. Curr Med Res Opin 1991; 12: 423-9
65. Schumacher HR, Boice J, Dahikh DI, et al. Randomized double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ 2002; 324: 1488-92
66. Gordon GV, Schumacher Jr HR. Management of gout. Am Fam Physician 1969; 10: 62-6
67. Gray RG, Tenenbaum J, Gottlieb NL. Local corticosteroid injection treatment in rheumatic disorders. Semin Arthritis Rheum 1979; 10: 231-54
68. Fernandez C, Noguera R, Gonzalez JA, et al. Treatment of acute attacks of gout with small doses of intraarticular triamcinolone acetonide. J Rheumatol 1999; 26: 2285-6
69. Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 1990; 19: 329-36
70. Alloway JA, Moriarty MJ, Hoogland YT, et al. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 1993; 20: 111-3
71. Getting SJ, Christian HC, Flower RJ, et al. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum 2002 Oct; 46 (10): 2765-75
72. Ritter J, Kerr LD, Valeriano-Marcet J, et al. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol 1994; 21: 696-9
73. Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988; 31: 803-5
74. Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of gouty arthritis. J Rheumatol 1994; 21: 1325-7
75. Li-Yu J, Clayburne G, Sieck M, et al. Treatment of chronic gout: can we determine when stores are depleted enough to prevent attacks of gout? J Rheumatol 2001; 28: 577-80
76. Gutman AB. Gout. In: Beeson PB. McDermott W, editors. Textbook of medicine. 12th ed. Philadelphia (PA): WB Saunders, 1958: 895
77. Fam AG. Should patients with interval gout be treated with urate lowering drugs? J Rheumatol 1995; 22: 1621-3
78. Emmerson BT. The management of gout. N Engl J Med 1996; 334: 455-551
79. Ferraz MB. An evidence based appraisal of the management of tophaceous interval gout. J Rheumatol 1995; 22: 1618-20
80. Perez-Ruiz F, Alonso-Ruiz A, Calaabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricemia: a pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998; 57 (9): 545-9
81. Hepburn AL, Kaye SA, Feber MD. Fenofibrate is a new treatment of hyperuricemia and gout? Ann Rheum Dis 2001; 60: 984-6
82. Shahinfar S, Simpson RL, Carides AD, et al. Safety of losartan in hypertensive patients with hyperuricemia. Kidney Int 1999; 56: 1879-85
83. Schumacher Jr HR, Moreno-Alvarez JM. Clued to common crystal induced arthropathies. Intern Med 1993; 14: 35-47
84. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum 1986; 29: 82-7
85. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76 (1): 47-56
86. Levinson DJ, Becker MA. Clinical gout and the pathogenesis of hyperuricemia. In: McCarty DJ, Koopman WJ, editors. Arthritis and allied conditions. 12th ed. Philadelphia (PA): Lea and Febriger, 1993: 1773-818
87. Bull PW, Scott JT. Intermittent control of hyperuricemia in the treatment of gout. J Rheumatol 1989; 16: 1246-8
88. Osada Y, Tsuchimoto M, Fukushima H, et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, febuxostat, in rodents. Eur J Pharmacol 1993; 241: 183-8
89. Komoriya K, Osada Y, Hasegawa M, et al. Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor febuxostat in chimpanzees. Eur J Pharmacol 1993; 250: 455-60
90. Swan S, Khosraven R, Mayer M, et al. Effect of renal impairment on pharmacokinetics, pharmacodynamics and safety of febuxostat (TMX-67), a novel non-purine selective inhibitor of xanthine oxidase [abstract]. Arthritis Rheum 2003; 48 Suppl. 9: 529
91. Joseph-Ridge N. Phase II, dose-response, safety and efficacy clinical trial of a new oral xanthine oxidase inhibitor TMX-67 (febuxostat) in subjects with gout [abstract]. Arthritis Rheum 2002; 46 Suppl. 9: 289
92. Bellamy N, Gilbert JR, Brooks PM, et al. A survey of current prescribing practices of anti-inflammatory and urate lowering drugs in gouty arthritis in the Province of Ontario. J Rheumatol 1988; 15: 1841-71
93. Medellin MV, Erickson AR, Enzenauer RJ. Variability of treatment for gouty arthritis between rheumatologists and primary care physicians. J Clin Rheumatol 1997; 3: 24-7
94. Pawlotsky Y. What is the optimal treatment for acute crystal induced arthritis? Rev Rheum Engl Ed 1996; 63: 231-3
95. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895-900
96. Weinberger A, Pinkhas J. The efficacy of treatment with allopurinol versus uricosuric drugs in gout. Panminerva Med 1978 Jul-Sep; 20 (3): 155-6
97. Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med 1966; 64: 229-58
98. Beutler AM, Rull M, Schlesinger N, et al. Treatment with allopurinol decreases the number of acute goul attacks despite persistently elevated serum uric acid [letter]. Clin Exp Rheumatol 2001; 19: 595
99. Scott JT. Comparison of allopurinol to probenecid. Ann Rheum Dis 1966; 25: 623-6
100. Altman A. Acute tumor lysis syndrome. Semin Oncol 2001; 28 (2 Suppl. 5): 3-8
101. Bomalaski JS, Clark MA. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. Curr Rheumatol Rep 2004 Jun; 6 (3): 240-7
102. Nishimura H, Matsushima A, Inada Y. Improved modification of yeast uricase with polyethylene glycol, accompanied with nonimmunoreactivity towards anti-uricase serum and high enzymic activity. Enzyme 1981; 26: 49-53
103. Bomalaski JS, Holtsberg FW, Ensor CM, et al. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J Rheumatol 2002 Sep; 29 (9): 1942-9
104. Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum 1998; 28: 48-59
105. Cohen A. Gout. Am J Med Sci 1936; 192; 448-93
106. Yu TF, Gutman AB. Efficacy of colchicine prophylaxis in gout. Ann Intern Med 1961; 55: 179-92
107. Yu TF. The efficacy of colchicine prophylaxis in articular gout - a reappraisal after 20 years. Semin Arthritis Rheum 1982; 12: 258-64